Search

Author/Creator Flaherty, Keith T

1. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Issue 10032 (14th May 2016)

Authors:
Haas, Naomi B; Manola, Judith; Uzzo, Robert G; Flaherty, Keith T; Wood, Christopher G; Kane, Christopher; Jewett, Michael; Dutcher, Janice P; Atkins, Michael B; Pins, Michael; Wilding, George; Cella, David; Wagner, Lynne; Matin, Surena; Kuzel, Timothy M; Sexton, Wade J; Wong, Yu-Ning; Choueiri, T...
Journal:
Lancet
Issue:
Volume 387:Issue 10032(2016)
Page Start:
2008
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Issue 3 (March 2018)

Authors:
McQuade, Jennifer L; Daniel, Carrie R; Hess, Kenneth R; Mak, Carmen; Wang, Daniel Y; Rai, Rajat R; Park, John J; Haydu, Lauren E; Spencer, Christine; Wongchenko, Matthew; Lane, Stephen; Lee, Dung-Yang; Kaper, Mathilde; McKean, Meredith; Beckermann, Kathryn E; Rubinstein, Samuel M; Rooney, Isabell...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 3(2018)
Page Start:
310
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Issue 3 (March 2021)

Authors:
Syeda, Mahrukh M; Wiggins, Jennifer M; Corless, Broderick C; Long, Georgina V; Flaherty, Keith T; Schadendorf, Dirk; Nathan, Paul D; Robert, Caroline; Ribas, Antoni; Davies, Michael A; Grob, Jean Jacques; Gasal, Eduard; Squires, Matthew; Marker, Mahtab; Garrett, James; Brase, Jan C; Polsky, David
Journal:
Lancet oncology
Issue:
Volume 22:Issue 3(2021)
Page Start:
370
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma. Issue 5 (11th April 2018)

Authors:
Echevarría‐Vargas, Ileabett M; Reyes‐Uribe, Patricia I; Guterres, Adam N; Yin, Xiangfan; Kossenkov, Andrew V; Liu, Qin; Zhang, Gao; Krepler, Clemens; Cheng, Chaoran; Wei, Zhi; Somasundaram, Rajasekharan; Karakousis, Giorgos; Xu, Wei; Morrissette, Jennifer JD; Lu, Yiling; Mills, Gordon B; Sullivan...
Journal:
EMBO molecular medicine
Issue:
Volume 10:Issue 5(2018)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Issue 7 (July 2017)

Authors:
Davies, Michael A; Saiag, Philippe; Robert, Caroline; Grob, Jean-Jacques; Flaherty, Keith T; Arance, Ana; Chiarion-Sileni, Vanna; Thomas, Luc; Lesimple, Thierry; Mortier, Laurent; Moschos, Stergios J; Hogg, David; Márquez-Rodas, Iván; Del Vecchio, Michele; Lebbé, Céleste; Meyer, Nicolas; Zhang, Y...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 7(2017:Jul.)
Page Start:
863
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Issue 5 (May 2018)

Authors:
Dummer, Reinhard; Ascierto, Paolo A; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A;...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 5(2018)
Page Start:
603
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Expanded access programmes: patient interests versus clinical trial integrity. Issue 1 (January 2015)

Authors:
Lorigan, Paul; Ascierto, Paolo A; Dummer, Reinhard; Eggermont, Alexander M; Flaherty, Keith T; Garbe, Claus; Gogas, Helen; Hauschild, Axel; Kefford, Richard F; Kirkwood, John M; Larkin, James; Long, Georgina V; Maio, Michele; McArthur, Grant A; Ribas, Antoni; Robert, Caroline; Schadendorf, Dirk; ...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 1(2015:Jan.)
Page Start:
15
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗